UPDATE 2-Novo plans larger study after encouraging semaglutide results

COPENHAGEN, Sept 16 (Reuters) - Novo Nordisk's

experimental injectable diabetes drug semaglutide reduced

cardiovascular risk by 26 percent, according to results released

on Friday, paving the way...

Read more